SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Engineering next-generation fusion proteins to dress the cell membrane with functionally enhanced receptors

DRESSCODE aims to revolutionize drug delivery by engineering recombinant proteins to enhance transmembrane receptors, enabling cost-effective therapies for angiogenesis and cancer immunotherapy.

Subsidie
€ 1.497.778
2024

Projectdetails

Introduction

No drug can be effective without an appropriate delivery system; this is why the development of formulations for effective and safe drug delivery currently raises major interests in all clinical applications. While the use of therapeutic proteins has substantially increased in the last four decades, there is an entire class of proteins that has not yet been explored as drugs: the transmembrane receptors.

Challenges in Delivery

In fact, the delivery of receptors for clinical applications remains very challenging and has only been achieved via genetic engineering of cells, referred to as gene therapy. To date, most gene therapies remain extremely expensive and therefore poorly accessible to patients.

DRESSCODE Proposal

DRESSCODE proposes to innovate cutting-edge protein engineering technologies to deliver and enhance receptors at the cell membrane, using recombinant proteins only. By doing so, we aim to create a paradigm shift from genetic engineering to protein engineering of the cell membrane, with the ambition of developing cost-effective protein-based therapies.

Engineering Approach

In DRESSCODE, we will first engineer independently the extracellular, intracellular, and transmembrane parts of a receptor, before combining our technologies to reconstruct functional receptors with enhanced bioactivity. Particularly, we will generate fusion proteins that:

  1. Target the cell surface with super-avidity, to enhance receptor sensing.
  2. Penetrate the cell membrane and target its inner side, to enhance receptor signaling.
  3. Insert across the cell membrane to reconstitute the receptor transmembrane domain using pH-low inserting peptides.

Clinical Applications

DRESSCODE will demonstrate Proof-of-Technologies in two high-impact clinical applications, focusing on the engineering of VEGFR-2 for therapeutic angiogenesis and of the CAR for T cell-based cancer immunotherapy. Its success will lead to the development of novel therapeutic proteins and inspire the future use of receptors as drugs, while providing valuable tools for biological research.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.497.778
Totale projectbegroting€ 1.497.778

Tijdlijn

Startdatum1-1-2024
Einddatum31-12-2028
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • UNIVERSITAETSKLINIKUM FREIBURGpenvoerder

Land(en)

Germany

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Protein function regulation through inserts for response to biological, chemical and physical signals

This project aims to develop a modular platform for engineering proteins to sense and respond to diverse signals, enhancing their functionality for innovative biomedical applications.

ERC Advanced...€ 2.500.000
2024
Details

Technology Of Protein delivery in Extracellular Vesicle-induced Cardiac Repair

TOP-EVICARE aims to enhance cardiac repair in heart failure by developing innovative protein loading systems in extracellular vesicles, ensuring effective delivery and commercialization.

ERC Proof of...€ 150.000
2023
Details

Membrane Micro-Compartments

The project aims to develop a system for in situ structural analysis of membrane proteins to enhance drug interaction studies and facilitate their commercialization in the pharmaceutical industry.

ERC Proof of...€ 150.000
2024
Details

Enabling efficient cell engineering leaving gene-expression BURden OUT for cell therapies and biopharmaceutical industry

BURnOUT is an AI-driven software designed to optimize gene sequences for efficient mammalian cell engineering, aiming to reduce costs and enhance therapies for cancer and biopharmaceuticals.

ERC Proof of...€ 150.000
2024
Details

Tuneable Conditional Control of Engineered Bacterial Therapeutics

This project aims to develop a modular synthetic receptor platform for precise control of engineered bacteria in cancer therapy, enhancing safety and efficacy through conditional therapeutic release.

ERC Proof of...€ 150.000
2023
Details
ERC Advanced...

Protein function regulation through inserts for response to biological, chemical and physical signals

This project aims to develop a modular platform for engineering proteins to sense and respond to diverse signals, enhancing their functionality for innovative biomedical applications.

ERC Advanced Grant
€ 2.500.000
2024
Details
ERC Proof of...

Technology Of Protein delivery in Extracellular Vesicle-induced Cardiac Repair

TOP-EVICARE aims to enhance cardiac repair in heart failure by developing innovative protein loading systems in extracellular vesicles, ensuring effective delivery and commercialization.

ERC Proof of Concept
€ 150.000
2023
Details
ERC Proof of...

Membrane Micro-Compartments

The project aims to develop a system for in situ structural analysis of membrane proteins to enhance drug interaction studies and facilitate their commercialization in the pharmaceutical industry.

ERC Proof of Concept
€ 150.000
2024
Details
ERC Proof of...

Enabling efficient cell engineering leaving gene-expression BURden OUT for cell therapies and biopharmaceutical industry

BURnOUT is an AI-driven software designed to optimize gene sequences for efficient mammalian cell engineering, aiming to reduce costs and enhance therapies for cancer and biopharmaceuticals.

ERC Proof of Concept
€ 150.000
2024
Details
ERC Proof of...

Tuneable Conditional Control of Engineered Bacterial Therapeutics

This project aims to develop a modular synthetic receptor platform for precise control of engineered bacteria in cancer therapy, enhancing safety and efficacy through conditional therapeutic release.

ERC Proof of Concept
€ 150.000
2023
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery

TraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs.

EIC Transition€ 2.498.963
2023
Details

A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system

The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.

EIC Pathfinder€ 2.988.377
2023
Details

New Prime Editing and non-viral delivery strategies for Gene Therapy

This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.

EIC Pathfinder€ 4.406.097
2022
Details

CAR T cells Rewired to prevent EXhaustion in the tumour microenvironment

CAR T-REX aims to enhance CAR T cell efficacy against solid tumors by integrating auto-regulated genetic circuits to prevent exhaustion, using advanced gene editing and delivery technologies.

EIC Pathfinder€ 2.733.931
2023
Details

Universal GPCR Activity Sensor for Next Generation Drug Discovery

This project aims to develop a novel single-assay technology platform for GPCR drug discovery, enhancing detection and classification of drug candidates to improve efficacy and reduce failures.

EIC Pathfinder€ 2.965.384
2023
Details
EIC Transition

TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery

TraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs.

EIC Transition
€ 2.498.963
2023
Details
EIC Pathfinder

A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system

The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.

EIC Pathfinder
€ 2.988.377
2023
Details
EIC Pathfinder

New Prime Editing and non-viral delivery strategies for Gene Therapy

This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.

EIC Pathfinder
€ 4.406.097
2022
Details
EIC Pathfinder

CAR T cells Rewired to prevent EXhaustion in the tumour microenvironment

CAR T-REX aims to enhance CAR T cell efficacy against solid tumors by integrating auto-regulated genetic circuits to prevent exhaustion, using advanced gene editing and delivery technologies.

EIC Pathfinder
€ 2.733.931
2023
Details
EIC Pathfinder

Universal GPCR Activity Sensor for Next Generation Drug Discovery

This project aims to develop a novel single-assay technology platform for GPCR drug discovery, enhancing detection and classification of drug candidates to improve efficacy and reduce failures.

EIC Pathfinder
€ 2.965.384
2023
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.